{
    "summary": "  * Skip to content\n  * Skip to navigation\n  * Skip to footer\n\n  * AstraZeneca Websites\n  * Global site \n\nSearch Menu\n\nSearch Search Search Close\n\n  * What science can do\n    * Stories \n    * Publications \n  * R&D\n    * R&D \n    * Our approach \n    * Precision medicine \n    * Transformative science \n    * Data science & AI \n    * Clinical innovation \n    * Digital health \n    * Our technologies \n    * Next generation therapeutics \n    * R&D strategic centres \n  * Our therapy areas\n    * All therapy areas \n    * Oncology \n    * BioPharmaceuticals \n    * Cardiovascular, Renal and Metabolism \n    * Respiratory & Immunology \n    * Vaccines and Immune Therapies \n    * Rare Disease \n    * Pipeline \n    * All medicines \n  * Our company\n    * Our company \n    * Our people \n    * Our leadership \n    * Cambridge \n    * Gothenburg \n    * Gaithersburg \n  * Careers \n    * Careers website \n    * Working with us \n    * Inclusion and diversity \n  * Investors\n    * Investor Relations (Global) \n    * Investor Relations (Sweden) \n    * Resources \n    * Governance \n    * Shareholder information \n    * Dividend policy \n    * Key facts \n    * FAQs \n    * Debt Investors \n    * ADR Programme \n  * Media\n    * Press Releases \n    * Media centre \n    * Articles \n    * Statements \n    * Image library \n    * Broadcast videos \n    * Archive \n    * Media contacts \n  * Sustainability\n    * Sustainability \n    * Access to healthcare \n    * Environmental protection \n    * Ethics and transparency \n    * Partnerships, alliances and recognition \n    * Supporting our communities \n    * Resources \n  * Partnering \n    * Partnering with AstraZeneca \n    * Our business development teams \n    * Our areas of partnering interest \n    * Why partner with AstraZeneca? \n    * Supplier Information \n    * A Catalyst Network \n  * More Hide\n\n#  What science can do\n\n* * *\n\n* * *\n\n## We are transforming the future of healthcare by unlocking the power of what\nscience can do, for people, society and planet.\n\n* * *\n\nDiscover more about our company\n\n* * *\n\n* * *\n\n* * *\n\n## Trending science story\n\nTranslational science: Decoding cancer's secrets\n\nWhat science can do stories\n\n##  Featured articles\n\nPutting Health at the Heart of COP28\n\nArticles\n\nAddressing the deeply inequitable human toll of noncommunicable diseases\n\nArticles\n\nKeep up to date with the latest media articles\n\n* * *\n\n> Kidney disease is not just one disease process - the patient population and\n> the underlying biology is highly heterogenous. Our research approach is to\n> target the different underlying molecular causes of disease, classifying\n> patients more accurately, and identifying new biomarkers and disease targets\n>\n> Martin Cowie, Interim Senior Vice President Late-Stage Development,\n> Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D,\n> AstraZeneca\n\nLearn more about our research to target proteinuria for chronic kidney disease\n\nDiscover how we champion inclusion and diversity at AstraZeneca\n\nWe have\n\n167\n\nprojects in our pipeline\n\nView pipeline\n\nExplore our precision medicine approach\n\nThe Discovery Centre in Cambridge (UK) is one of our three global science\ncentres\n\nExplore all our science centres\n\n* * *\n\n##  Our Sustainability ambition\n\nCorporate Press Release\n\nImfinzi plus transarterial chemoembolisation (TACE) and bevacizumab reduced\nthe risk of disease progression or death by 23% vs. TACE in liver cancer\neligible for embolisation\n\n19 January 2024\n\nCorporate Press Release\n\nVoydeya (danicopan) granted first-ever regulatory approval in Japan for adults\nwith PNH to be used in combination with C5 inhibitor therapy\n\n19 January 2024\n\n###  AstraZeneca Websites\n\nThis website is intended for people seeking information on AstraZeneca's\nworldwide business. Our country sites can be located in the AZ Network.\n\n* * *\n\nVeeva ID: Z4-46798  \nDate of next review: August 2024\n\n### Resources\n\n  * All resources\n  * Open Innovation\n  * Externally sponsored scientific research\n  * Medical Information for HCPs\n  * US prescription assistance programmes\n  * Global clinical trials information\n  * Medicines\n  * Report a possible side effect\n\n### Quick links\n\n  * Media \n  * Investor Relations\n  * Partnering\n  * Careers\n  * Sustainability\n  * Modern Slavery Statement\n  * AZethics \u2013 Report A Concern\n  * Supplier information\n  * Social Media Community Guidelines\n\n### Social Media\n\n  * Linkedn\n  * Instagram\n  * Facebook\n  * Twitter\n  * YouTube\n  * Glassdoor\n\n#### utility links\n\n  * Legal notice and Terms of Use\n  * Privacy notice\n  * Site map\n  * Contact us\n  * Cookie policy\n\n\u00a9 AstraZeneca 2024\n\n**You are now leaving AstraZeneca.com**\n\nYou have selected a link that will take you to a site maintained by a third\nparty who is solely responsible for its contents.\n\nAstraZeneca provides this link as a service to website visitors. AstraZeneca\nis not responsible for the privacy policy of any third party websites. We\nencourage you to read the privacy policy of every website you visit.\n\nClick \u2018cancel\u2019 to return to AstraZeneca\u2019s site or \u2018continue\u2019 to proceed.\n\nCancel Continue\n\n**Important notice for users**  \n  \nYou are about to access AstraZeneca historic archive material. Any reference\nin these archives to AstraZeneca products or their uses may not reflect\ncurrent medical knowledge and should not be used as a source of information on\nthe present product label, efficacy data or safety data. Please refer to your\napproved national product label (SmPC) for current product information.  \n  \nI have read this warning and will not be using any of the contained product\ninformation for clinical purposes.\n\nI disagree I agree\n\n",
    "links": "[{\"link\": \"https://www.astrazeneca.com/\", \"text\": \"\"}, {\"link\": \"https://www.astrazeneca.com/global/en/AstraZeneca-Websites.html\", \"text\": \"AstraZeneca Websites\"}, {\"link\": \"https://www.astrazeneca.com/what-science-can-do.html\", \"text\": \"\\nWhat science can do\"}, {\"link\": \"https://www.astrazeneca.com/what-science-can-do.html\", \"text\": \"Stories\\n\"}, {\"link\": \"https://www.astrazeneca.com/publication.html\", \"text\": \"Publications\\n\"}, {\"link\": \"https://www.astrazeneca.com/r-d.html\", \"text\": \"\\nR&D\"}, {\"link\": \"https://www.astrazeneca.com/r-d.html\", \"text\": \"R&D\\n\"}, {\"link\": \"https://www.astrazeneca.com/r-d/our-approach.html\", \"text\": \"Our approach\\n\"}, {\"link\": \"https://www.astrazeneca.com/r-d/precision-medicine.html\", \"text\": \"Precision medicine\\n\"}, {\"link\": \"https://www.astrazeneca.com/r-d/transformative-science.html\", \"text\": \"Transformative science\\n\"}, {\"link\": \"https://www.astrazeneca.com/r-d/data-science-and-ai.html\", \"text\": \"Data science & AI\\n\"}, {\"link\": \"https://www.astrazeneca.com/r-d/clinical-innovation.html\", \"text\": \"Clinical innovation\\n\"}, {\"link\": \"https://www.astrazeneca.com/r-d/digital-health-revolutionising-healthcare-for-patients.html\", \"text\": \"Digital health\\n\"}, {\"link\": \"https://www.astrazeneca.com/r-d/our-technologies.html\", \"text\": \"Our technologies\\n\"}, {\"link\": \"https://www.astrazeneca.com/r-d/next-generation-therapeutics.html\", \"text\": \"Next generation therapeutics\\n\"}, {\"link\": \"https://www.astrazeneca.com/r-d/our-strategic-r-d-centres.html\", \"text\": \"R&D strategic centres\\n\"}, {\"link\": \"https://www.astrazeneca.com/our-therapy-areas.html\", \"text\": \"\\nOur therapy areas\"}, {\"link\": \"https://www.astrazeneca.com/our-therapy-areas.html\", \"text\": \"All therapy areas\\n\"}, {\"link\": \"https://www.astrazeneca.com/our-therapy-areas/oncology.html\", \"text\": \"Oncology\\n\"}, {\"link\": \"https://www.astrazeneca.com/our-therapy-areas/biopharmaceuticals.html\", \"text\": \"BioPharmaceuticals\\n\"}, {\"link\": \"https://www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism.html\", \"text\": \"Cardiovascular, Renal and Metabolism\\n\"}, {\"link\": \"https://www.astrazeneca.com/our-therapy-areas/respiratory-and-immunology.html\", \"text\": \"Respiratory & Immunology\\n\"}, {\"link\": \"https://www.astrazeneca.com/our-therapy-areas/vaccines-and-immune-therapies.html\", \"text\": \"Vaccines and Immune Therapies\\n\"}, {\"link\": \"https://www.astrazeneca.com/our-therapy-areas/rare-disease.html\", \"text\": \"Rare Disease\\n\"}, {\"link\": \"https://www.astrazeneca.com/our-therapy-areas/pipeline.html\", \"text\": \"Pipeline\\n\"}, {\"link\": \"https://www.astrazeneca.com/our-therapy-areas/medicines.html\", \"text\": \"All medicines\\n\"}, {\"link\": \"https://www.astrazeneca.com/our-company.html\", \"text\": \"\\nOur company\"}, {\"link\": \"https://www.astrazeneca.com/our-company.html\", \"text\": \"Our company\\n\"}, {\"link\": \"https://www.astrazeneca.com/our-company/our-people.html\", \"text\": \"Our people\\n\"}, {\"link\": \"https://www.astrazeneca.com/our-company/leadership.html\", \"text\": \"Our leadership\\n\"}, {\"link\": \"https://www.astrazeneca.com/our-company/our-locations/cambridge.html\", \"text\": \"Cambridge\\n\"}, {\"link\": \"https://www.astrazeneca.com/our-company/our-locations/gothenburg.html\", \"text\": \"Gothenburg\\n\"}, {\"link\": \"https://www.astrazeneca.com/our-company/our-locations/gaithersburg.html\", \"text\": \"Gaithersburg\\n\"}, {\"link\": \"https://www.astrazeneca.com/our-company/great-place-to-work.html\", \"text\": \"Working with us\\n\"}, {\"link\": \"https://www.astrazeneca.com/Sustainability/ethics-and-transparency/inclusion-and-diversity.html\", \"text\": \"Inclusion and diversity\\n\"}, {\"link\": \"https://www.astrazeneca.com/investor-relations.html\", \"text\": \"\\nInvestors\"}, {\"link\": \"https://www.astrazeneca.com/investor-relations.html\", \"text\": \"\"}, {\"link\": \"https://www.astrazeneca.com/investor-relations/resources.html\", \"text\": \"Resources\\n\"}, {\"link\": \"https://www.astrazeneca.com/investor-relations/corporate-governance.html\", \"text\": \"Governance\\n\"}, {\"link\": \"https://www.astrazeneca.com/investor-relations/shareholder-information.html\", \"text\": \"Shareholder information\\n\"}, {\"link\": \"https://www.astrazeneca.com/investor-relations/dividend-policy.html\", \"text\": \"Dividend policy\\n\"}, {\"link\": \"https://www.astrazeneca.com/investor-relations/key-facts.html\", \"text\": \"Key facts\\n\"}, {\"link\": \"https://www.astrazeneca.com/investor-relations/faqs.html\", \"text\": \"FAQs\\n\"}, {\"link\": \"https://www.astrazeneca.com/investor-relations/debt-investors.html\", \"text\": \"Debt Investors\\n\"}, {\"link\": \"https://www.astrazeneca.com/investor-relations/astrazeneca-adr-programme.html\", \"text\": \"ADR Programme\\n\"}, {\"link\": \"https://www.astrazeneca.com/media-centre.html\", \"text\": \"\\nMedia\"}, {\"link\": \"https://www.astrazeneca.com/media-centre/press-releases.html\", \"text\": \"Press Releases\\n\"}, {\"link\": \"https://www.astrazeneca.com/media-centre.html\", \"text\": \"Media centre\\n\"}, {\"link\": \"https://www.astrazeneca.com/media-centre/articles.html\", \"text\": \"Articles\\n\"}, {\"link\": \"https://www.astrazeneca.com/media-centre/statements.html\", \"text\": \"Statements\\n\"}, {\"link\": \"https://www.astrazeneca.com/media-centre/image-and-broadcast-library.html\", \"text\": \"Image library\\n\"}, {\"link\": \"https://www.astrazeneca.com/media-centre/Broadcast.html\", \"text\": \"Broadcast videos\\n\"}, {\"link\": \"https://www.astrazeneca.com/media-centre/archive.html\", \"text\": \"Archive\\n\"}, {\"link\": \"https://www.astrazeneca.com/media-centre/contacts.html\", \"text\": \"Media contacts\\n\"}, {\"link\": \"https://www.astrazeneca.com/Sustainability.html\", \"text\": \"\\nSustainability\"}, {\"link\": \"https://www.astrazeneca.com/Sustainability.html\", \"text\": \"Sustainability\\n\"}, {\"link\": \"https://www.astrazeneca.com/Sustainability/access-to-healthcare.html\", \"text\": \"Access to healthcare\\n\"}, {\"link\": \"https://www.astrazeneca.com/Sustainability/environmental-protection.html\", \"text\": \"Environmental protection\\n\"}, {\"link\": \"https://www.astrazeneca.com/Sustainability/ethics-and-transparency.html\", \"text\": \"Ethics and transparency\\n\"}, {\"link\": \"https://www.astrazeneca.com/Sustainability/partnerships-alliances-and-recognition.html\", \"text\": \"Partnerships, alliances and recognition\\n\"}, {\"link\": \"https://www.astrazeneca.com/Sustainability/supporting-our-communities.html\", \"text\": \"Supporting our communities\\n\"}, {\"link\": \"https://www.astrazeneca.com/Sustainability/resources.html\", \"text\": \"Resources\\n\"}, {\"link\": \"https://www.astrazeneca.com/partnering.html\", \"text\": \"\\nPartnering \"}, {\"link\": \"https://www.astrazeneca.com/partnering.html\", \"text\": \"Partnering with AstraZeneca\\n\"}, {\"link\": \"https://www.astrazeneca.com/partnering/our-partnering-teams.html\", \"text\": \"Our business development teams\\n\"}, {\"link\": \"https://www.astrazeneca.com/partnering/our-areas-of-partnering-interest.html\", \"text\": \"Our areas of partnering interest\\n\"}, {\"link\": \"https://www.astrazeneca.com/partnering/why-partner-with-astrazeneca.html\", \"text\": \"Why partner with AstraZeneca?\\n\"}, {\"link\": \"https://www.astrazeneca.com/az-suppliers.html\", \"text\": \"Supplier Information\\n\"}, {\"link\": \"https://www.astrazeneca.com/partnering/a-catalyst-network.html\", \"text\": \"A Catalyst Network\\n\"}, {\"link\": \"https://www.astrazeneca.com/our-company.html\", \"text\": \"\"}, {\"link\": \"https://www.astrazeneca.com/what-science-can-do/topics/technologies/translational-science.html\", \"text\": \"\"}, {\"link\": \"https://www.astrazeneca.com/what-science-can-do/topics/technologies/translational-science.html\", \"text\": \"\\nTranslational science: Decoding cancer's secrets\\n\"}, {\"link\": \"https://www.astrazeneca.com/what-science-can-do.html\", \"text\": \"\\nWhat science can do stories\\n\"}, {\"link\": \"https://www.astrazeneca.com/media-centre/articles/2023/putting-health-at-the-heart-of-cop28.html\", \"text\": \"\"}, {\"link\": \"https://www.astrazeneca.com/media-centre/articles/2023/putting-health-at-the-heart-of-cop28.html\", \"text\": \"Putting Health at the Heart of COP28\"}, {\"link\": \"https://www.astrazeneca.com/media-centre/articles.html\", \"text\": \"\\nArticles\\n\"}, {\"link\": \"https://www.astrazeneca.com/media-centre/articles/2023/ncd-toll-deeply-inequitable.html\", \"text\": \"\"}, {\"link\": \"https://www.astrazeneca.com/media-centre/articles/2023/ncd-toll-deeply-inequitable.html\", \"text\": \"Addressing the deeply inequitable human toll of noncommunicable diseases\"}, {\"link\": \"https://www.astrazeneca.com/media-centre/articles.html\", \"text\": \"\\nArticles\\n\"}, {\"link\": \"https://www.astrazeneca.com/media-centre/articles.html\", \"text\": \"\"}, {\"link\": \"https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/high-proteinuria-chronic-kidney-disease.html\", \"text\": \"Learn more about our research to target proteinuria for chronic kidney disease\"}, {\"link\": \"https://www.astrazeneca.com/Sustainability/ethics-and-transparency/inclusion-and-diversity.html\", \"text\": \"\\nDiscover how we champion inclusion and diversity at AstraZeneca\\n\"}, {\"link\": \"https://www.astrazeneca.com/our-therapy-areas/pipeline.html\", \"text\": \"\"}, {\"link\": \"https://www.astrazeneca.com/r-d/precision-medicine.html\", \"text\": \"\\nExplore our precision medicine approach\\n\"}, {\"link\": \"https://www.astrazeneca.com/our-company/our-locations/cambridge.html\", \"text\": \"The Discovery Centre in Cambridge (UK) is one of our three global science centres \"}, {\"link\": \"https://www.astrazeneca.com/r-d/our-strategic-r-d-centres.html\", \"text\": \"\\nExplore all our science centres\\n\"}, {\"link\": \"https://www.astrazeneca.com/Sustainability.html\", \"text\": \"\"}, {\"link\": \"https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-with-tace-and-bevacizumab-in-patients-with-hepatocellular-carcinoma-eligible-for-embolisation.html\", \"text\": \"Imfinzi plus transarterial chemoembolisation (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolisation\"}, {\"link\": \"https://www.astrazeneca.com/media-centre/press-releases/2024/voydeya-danicopan-granted-first-ever-regulatory-approval-in-japan-for-adults-with-pnh-to-be-used-in-combination-with-c5-inhibitor-therapy.html\", \"text\": \"Voydeya (danicopan) granted first-ever regulatory approval in Japan for adults with PNH to be used in combination with C5 inhibitor therapy\"}, {\"link\": \"https://www.astrazeneca.com/global/en/AstraZeneca-Websites.html\", \"text\": \"AstraZeneca Websites\"}, {\"link\": \"https://www.astrazeneca.com/global/en/Resources.html\", \"text\": \"All resources\"}, {\"link\": \"https://www.astrazeneca.com/partnering/externally-sponsored-scientific-research.html\", \"text\": \"Externally sponsored scientific research\"}, {\"link\": \"https://www.astrazeneca.com/our-therapy-areas/medicines.html\", \"text\": \"Medicines\"}, {\"link\": \"https://www.astrazeneca.com/media-centre.html\", \"text\": \"Media \"}, {\"link\": \"https://www.astrazeneca.com/investor-relations.html\", \"text\": \"Investor Relations\"}, {\"link\": \"https://www.astrazeneca.com/partnering.html\", \"text\": \"Partnering\"}, {\"link\": \"https://www.astrazeneca.com/sustainability.html\", \"text\": \"Sustainability\"}, {\"link\": \"https://www.astrazeneca.com/content/dam/az/PDF/Sustainability/Modern_Slavery_Act_Statement.pdf\", \"text\": \"Modern Slavery Statement\"}, {\"link\": \"https://www.astrazeneca.com/az-suppliers.html\", \"text\": \"Supplier information\"}, {\"link\": \"https://www.astrazeneca.com/media-centre/social-media-community-guidelines.html\", \"text\": \"Social Media Community Guidelines\"}, {\"link\": \"https://www.astrazeneca.com/legal-notice-and-terms-of-use.html\", \"text\": \"Legal notice and Terms of Use\"}, {\"link\": \"https://www.astrazeneca.com/global/en/sitemap.html\", \"text\": \"Site map\"}, {\"link\": \"https://www.astrazeneca.com/our-company/Contact-us.html\", \"text\": \"Contact us\"}, {\"link\": \"https://policy.cookiereports.com/510df253-en-gb.html\", \"text\": \"Cookie policy\"}]",
    "priceAndPlans": "Error: Timeout 30000ms exceeded. =========================== logs\n=========================== navigating to\n\"http://web.archive.org/web/20240119011450/https://www.astrazeneca.com/\",\nwaiting until \"load\"\n============================================================\n\n"
}